Medical/Pharmaceuticals

AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy

SUZHOU, China, May 12, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting being held from May 13-17...

2025-05-12 20:00 2224

Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ‌Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希® ), the first domestically approved antibody-drug conjugate (ADC...

2025-05-12 16:29 4959

Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain

HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof.Mike Chan's longstanding vision of organ-specific, cell-specific regenerative medicine. This pivotal research[1], authored b...

2025-05-12 15:44 2880

VUNO's AI-Powered Cardiac Arrest Risk Management System Earns CE MDR and UKCA Certifications

* Early Regulatory Approval Accelerates Expansion Plans in Europe and the Middle East SEOUL, South Korea, May 12, 2025 /PRNewswire/ -- VUNO, a leading South Korean medical AI company, announced today that its flagship AI-powered cardiac arrest risk management system VUNO Med®-DeepCARS®(DeepCARS...

2025-05-12 15:22 3251

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596, an allogeneic BCMA-targeted CAR-T developed using the THANK-u Plus™ platform. CT0596...

2025-05-12 08:00 2372

Major strategic engagement program to create greater awareness of fertility health issues in the APAC region

SINGAPORE, May 12, 2025 /PRNewswire/ -- The Asia Pacific Initiative on Reproduction (ASPIRE) – the peak body harnessing expertise in assisted conception throughout the region – will embark on a major public education and awareness program on fertility health. It is also working to broaden its ...

2025-05-12 05:23 2538

Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025

SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-drivenclinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation onSKG1108, its investigational optogenetic gen...

2025-05-11 00:00 3976

Mediso completes Cryo-Free MRI Magnet Tech Transfer from SSI

BUDAPEST, Hungary, May 9, 2025 /PRNewswire/ -- Mediso is pleased to announce the successful completion of the first phase of a strategic technology transfer agreement with Superconducting Systems Inc. (SSI), a fully owned subsidiary of IMRIS. This agreement marks a significant milestone in Mediso...

2025-05-09 21:00 3461

Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical ("Qilu") for the development, manufacturing, and commercialization of its B7-H3 AD...

2025-05-09 18:00 7415

IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel

SHANGHAI, NANJING, China and SAN FRANCISCO, May 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed BC...

2025-05-09 16:25 2912

Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring

A landmark study recently published in March 2025 by JCO Oncology Advances, demonstrates the potential ofK-TRACKTM in monitoring treatment response and assessing recurrence risk among 623 Solid-Tumor Patients of six cancer types (lung, colorectal, bre...

2025-05-09 14:01 2888

THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA

BANGKOK, May 9, 2025 /PRNewswire/ -- A professor from Chulalongkorn University's Faculty of Science has developed a skincare formula using microbiome and 4P-biotics technology, resulting in a serum and sunscreen lotion under the brand THANARA. These products help bala...

2025-05-09 10:00 2646

DNV recognized as a Notified Body for Certification under In Vitro Diagnostic Regulation (IVDR)

OSLO, Norway, May 8, 2025 /PRNewswire/ -- DNV, the independent assurance and risk management provider, has been recognized by the European Commission as a notified body for the certification of devices under the European Union's In Vitro Diagnostic Regulation (IVDR). The designation increases cap...

2025-05-08 22:38 3515

Datasea Pre-Announces Estimated Third Quarter Revenue of approximately $51.9 Million, up approximately 164.6% Year-over-Year

Expects to Achieve Projected Annual Revenue of $90 Million BEIJING, May 8, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced its...

2025-05-08 21:30 4914

From Patient to Pioneer: jinIX Supports Nathan Ehrlich's Mission for Rare Disease Research

SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- The  jinIX Foundation hosted a meaningful and inspiring gathering—not just to mark the launch of its non-profit initiative, but to honor Nathan Ehrlich, a young rare disease advocate whose courage and vision ...

2025-05-08 20:35 2163

BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate

* BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. * JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing anext-generation therapeutic. * BioDlink provided end-to-end devel...

2025-05-08 20:30 4423

Colorcon and ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical and Nutraceutical Industries

HARLEYSVILLE, Pa. and MUMBAI, India, May 8, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the healthcare industry, today announced an exclusive partnership with ASHA Cellulose, ...

2025-05-08 17:00 2424

Nordic Bioscience announces PRO-C3 launched by Roche Diagnostics on cobas analysers

HERLEV, Denmark, May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity – a disease r...

2025-05-08 16:49 2783

QDX Congratulates Co-Founder and Head of Research A/Prof. Giuseppe Barca on Receiving the 2025 Dirac Medal

SINGAPORE, May 8, 2025 /PRNewswire/ -- QDX proudly congratulates its Co-Founder and Head of Research,A/Prof. Giuseppe Barca, on being awarded the 2025 Dirac Medal, the highest international honour for early-career researchers in theoretical and computational chemistry. Presented by the World Ass...

2025-05-08 16:10 2570

Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025

* Penetrium™ Achieves Historic Breakthrough * Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy * Presented at AACR 2025, Chicago CHICAGO, May 7, 2025 /PRNewswire/ -- Hyundai Bioscience presented the results of its Penetrium™ combinati...

2025-05-08 09:03 4020
1 ... 979899100101102103 ... 646

Week's Top Stories